Anna Robeva

3.3k total citations
40 papers, 1.9k citations indexed

About

Anna Robeva is a scholar working on Molecular Biology, Pulmonary and Respiratory Medicine and Physiology. According to data from OpenAlex, Anna Robeva has authored 40 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Molecular Biology, 15 papers in Pulmonary and Respiratory Medicine and 11 papers in Physiology. Recurrent topics in Anna Robeva's work include Receptor Mechanisms and Signaling (14 papers), Lung Cancer Treatments and Mutations (14 papers) and Adenosine and Purinergic Signaling (11 papers). Anna Robeva is often cited by papers focused on Receptor Mechanisms and Signaling (14 papers), Lung Cancer Treatments and Mutations (14 papers) and Adenosine and Purinergic Signaling (11 papers). Anna Robeva collaborates with scholars based in United States, Switzerland and Germany. Anna Robeva's co-authors include Joel Linden, Diane L. Rosin, Patrice G. Guyenet, Heidi Taylor, Amy L. Tucker, Rüdiger Vallon, Xiaowei Jin, Patricia Burfeind, Andrea B. Huber and Klemens Kaupmann and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and Journal of Neuroscience.

In The Last Decade

Anna Robeva

38 papers receiving 1.8k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Anna Robeva United States 18 870 705 659 206 197 40 1.9k
Annick Raas‐Rothschild Israel 34 1.7k 1.9× 661 0.9× 262 0.4× 233 1.1× 140 0.7× 108 3.8k
Jill M. Weimer United States 26 955 1.1× 162 0.2× 357 0.5× 100 0.5× 115 0.6× 82 2.1k
Daniela Merlo Italy 30 834 1.0× 142 0.2× 766 1.2× 82 0.4× 81 0.4× 59 2.0k
Elena Sokolova Russia 25 983 1.1× 356 0.5× 277 0.4× 156 0.8× 69 0.4× 40 1.6k
Alfredo Rodríguez Antigüedad Spain 17 368 0.4× 266 0.4× 228 0.3× 149 0.7× 44 0.2× 59 1.4k
Cécile Delarasse France 22 508 0.6× 433 0.6× 242 0.4× 109 0.5× 34 0.2× 43 2.0k
Wang Zheng China 21 721 0.8× 63 0.1× 343 0.5× 103 0.5× 159 0.8× 43 1.5k
Kinga Szigeti United States 24 933 1.1× 95 0.1× 812 1.2× 333 1.6× 276 1.4× 64 2.9k
Fabrizio Vacca Italy 17 573 0.7× 413 0.6× 210 0.3× 171 0.8× 41 0.2× 19 1.4k
Fabio Bianco Italy 17 926 1.1× 432 0.6× 193 0.3× 60 0.3× 56 0.3× 29 1.8k

Countries citing papers authored by Anna Robeva

Since Specialization
Citations

This map shows the geographic impact of Anna Robeva's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anna Robeva with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anna Robeva more than expected).

Fields of papers citing papers by Anna Robeva

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Anna Robeva. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anna Robeva. The network helps show where Anna Robeva may publish in the future.

Co-authorship network of co-authors of Anna Robeva

This figure shows the co-authorship network connecting the top 25 collaborators of Anna Robeva. A scholar is included among the top collaborators of Anna Robeva based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Anna Robeva. Anna Robeva is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Wolf, Jürgen, et al.. (2022). Capmatinib in MET exon 14-mutated advanced NSCLC: updated results from the GEOMETRY mono-1 study.. Pneumologie. 76(S 01). S39–S40. 7 indexed citations
3.
Heist, Rebecca S., Johan Vansteenkiste, Egbert F. Smit, et al.. (2021). MO01.21 Phase 2 GEOMETRY Mono-1 Study: Capmatinib in Patients with METex14-mutated Advanced Non-Small Cell Lung Cancer who Received Prior Immunotherapy. Journal of Thoracic Oncology. 16(1). S24–S25.
4.
Heist, Rebecca S., Jennifer Moriatis Wolf, Takashi Seto, et al.. (2019). OA01.07 Capmatinib (INC280) in METΔEX14-Mutated Advanced NSCLC: Efficacy Data from the Phase 2 Geometry MONO-1 Study. Journal of Thoracic Oncology. 14(11). S1126–S1126. 4 indexed citations
5.
Heist, Rebecca S., Takashi Seto, Ji‐Youn Han, et al.. (2019). CMET-22. CAPMATINIB (INC280) IN METΔEX14-MUTATED ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC): EFFICACY DATA FROM THE PHASE 2 GEOMETRY MONO-1 STUDY. Neuro-Oncology. 21(Supplement_6). vi56–vi56. 13 indexed citations
6.
Séchaud, Romain, et al.. (2008). Absolute Oral Bioavailability and Disposition of Deferasirox in Healthy Human Subjects. The Journal of Clinical Pharmacology. 48(8). 919–925. 25 indexed citations
7.
Séchaud, Romain, et al.. (2008). Absence of an effect of a single-dose deferasirox on the steady-state pharmacokinetics of digoxin. International Journal of Clinical Pharmacology and Therapeutics. 46(10). 519–526. 4 indexed citations
8.
Singer, Jonathan B., Yaping Shou, Francis J. Giles, et al.. (2007). UGT1A1 promoter polymorphism increases risk of nilotinib-induced hyperbilirubinemia. Leukemia. 21(11). 2311–2315. 91 indexed citations
9.
Robeva, Anna, Yan Yan‐Neale, Patricia Burfeind, et al.. (2003). Rapid expression cloning of receptors using epitope‐tagged ligands and high‐speed cell sorting. Cytometry Part A. 51A(2). 59–67. 2 indexed citations
10.
Lee, Deborah, Anna Robeva, Zhongjian Chen, & Kenneth P. Minneman. (2003). Mutational Uncoupling of α1A-Adrenergic Receptors from G Proteins Also Uncouples Mitogenic and Transcriptional Responses in PC12 Cells. Journal of Pharmacology and Experimental Therapeutics. 306(2). 471–477. 5 indexed citations
11.
Vicentic, Aleksandra, Anna Robeva, George A. Rogge, Michelle A. Uberti, & Kenneth P. Minneman. (2002). Biochemistry and Pharmacology of Epitope-Tagged α1-Adrenergic Receptor Subtypes. Journal of Pharmacology and Experimental Therapeutics. 302(1). 58–65. 50 indexed citations
12.
13.
Vallon, Rüdiger, Felix Freuler, Anna Robeva, et al.. (2001). Serum Amyloid A (apoSAA) Expression Is Up-Regulated in Rheumatoid Arthritis and Induces Transcription of Matrix Metalloproteinases. The Journal of Immunology. 166(4). 2801–2807. 140 indexed citations
14.
Zhong, Hongying, Deborah Lee, Anna Robeva, & Kenneth P. Minneman. (2001). Signaling pathways activated by α1-adrenergic receptor subtypes in PC12 cells. Life Sciences. 68(19-20). 2269–2276. 14 indexed citations
15.
Gao, Zhenhai, Anna Robeva, & Joel Linden. (1999). Purification of A1 adenosine receptor‒G-protein complexes: effects of receptor down-regulation and phosphorylation on coupling. Biochemical Journal. 338(3). 729–729. 11 indexed citations
16.
Robeva, Anna, et al.. (1996). Double tagging recombinant A1- and A2A-adenosine receptors with hexahistidine and the FLAG epitope. Biochemical Pharmacology. 51(4). 545–555. 67 indexed citations
17.
Linden, Joel, Heidi Taylor, Anna Robeva, et al.. (1993). Molecular cloning and functional expression of a sheep A3 adenosine receptor with widespread tissue distribution.. Molecular Pharmacology. 44(3). 524–532. 169 indexed citations
18.
Tucker, Amy L., et al.. (1992). Cloning and expression of a bovine adenosine A1 receptor cDNA. FEBS Letters. 297(1-2). 107–111. 44 indexed citations
19.
Popova, J., et al.. (1991). Beta-adrenoceptor activity change after prolonged treatment with growth hormone and somatostatin. Comparative Biochemistry and Physiology Part C Comparative Pharmacology. 100(3). 543–546. 3 indexed citations
20.
Popova, J., et al.. (1990). Muscarinic receptor activity change after prolonged treatment with growth hormone and somatostatin. Comparative Biochemistry and Physiology Part C Comparative Pharmacology. 96(1). 119–123. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Annick Raas‐Rothschild Breakdown of academic impact, for papers by Jill M. Weimer Breakdown of academic impact, for papers by Daniela Merlo Breakdown of academic impact, for papers by Elena Sokolova Breakdown of academic impact, for papers by Alfredo Rodríguez Antigüedad Breakdown of academic impact, for papers by Cécile Delarasse Breakdown of academic impact, for papers by Wang Zheng Breakdown of academic impact, for papers by Kinga Szigeti Breakdown of academic impact, for papers by Fabrizio Vacca Breakdown of academic impact, for papers by Fabio Bianco
Rankless by CCL
2026